logo

For the Inventor, By the Inventor

Tokyo, Japan

Teijin Pharma Limited


USPTO Granted Patents = 126



Forward Citations = 1,013

Loading Chart...
Loading Chart...

301 inventors (with patents filed for the assignee):

goldMedal Keiko Omura (11 out of 11 patents)

silverMedal Shinya Fujimoto (10 out of 10 patents)

bronzeMedal Gen Unoki (9 out of 10 patents)

4.  Takamitsu Okayama (7 out of 7 patents)

5.  Yoshimasa Takahashi (7 out of 13 patents)

6.  Hideo Nawata (7 out of 7 patents)

7.  Hiroshi H Eguchi (7 out of 48 patents)

8.  Akihiro Maeda (6 out of 14 patents)

9.  Akira Tanokura (6 out of 7 patents)

10.  Masahide Takishita (6 out of 6 patents)

11.  Tongoh Chin (6 out of 6 patents)

12.  Fumi Fujita (5 out of 5 patents)

13.  Jun Takeda (5 out of 85 patents)

14.  Sadayoshi Matsumoto (5 out of 5 patents)

15.  Hideharu Shimura (5 out of 7 patents)


Core Competencies:
Oxygen Concentrator
Phototherapy Device
Humanized Antibody
Cognitive Disorders
Respiratory Information Acquisition
Transcranial Magnetic Stimulation
Therapeutic Electromagnetic Stimulation
Gas Supply Device
Congestive Heart Failure Therapy
Training Device
Benzimidazole Derivatives
Magnetic Stimulation Device

126 patents:

1. 12502550 - Light beam irradiation apparatus (2025-12-23),
2. 12492185 - Benzimidazole derivatives and their uses (2025-12-09),
3. 12465714 - Oxygen concentrator, control method, and control program (2025-11-11),
4. 12458916 - Oxygen concentration device (2025-11-04),
5. 12415089 - Phototherapy device and method of operation of phototherapy device (2025-09-16),
6. 12227563 - Anti-IGF-I receptor humanized antibody (2025-02-18),
7. 12151123 - Phototherapy device (2024-11-26),
8. 12109359 - Oxygen supply device and method for controlling same (2024-10-08),
9. 11951261 - Nitric oxide administration device (2024-04-09),
10. 11951256 - Oxygen therapy system (2024-04-09),
11. 11739143 - Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same (2023-08-29),
12. 11690971 - Exacerbation predicting device, oxygen concentrating device, and exacerbation predicting system (2023-07-04),
13. 11667707 - SPNS2 neutralizing antibody (2023-06-06),
14. 11666718 - Respiratory information acquisition device and respiratory information acquisition method (2023-06-06),
15. 11629194 - Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies (2023-04-18),
Teijin Pharma Limited is a global pharmaceutical company that focuses on the research, development, manufacturing, and marketing of innovative pharmaceutical products. With a commitment to improving the health and well-being of people worldwide, Teijin Pharma combines advanced technologies and scientific expertise to provide effective therapies for various medical conditions. The company operates across multiple therapeutic areas, including cardiovascular diseases, respiratory disorders, metabolic disorders, and central nervous system disorders.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

126 Patents

#425 in Tokyo

#954 in Japan

#6,194 in the World

...
Tokyo, Japan

Teijin Pharma Limited

Forward Citations = 1,013

301 inventors:

goldMedal Keiko Omura (11 out of 11 patents)

silverMedal Shinya Fujimoto (10 out of 10 patents)

bronzeMedal Gen Unoki (9 out of 10 patents)

4.  Takamitsu Okayama (7 out of 7 patents)

5.  Yoshimasa Takahashi (7 out of 13 patents)

Please report any incorrect information to support@idiyas.com
Loading…